The company's lead candidate Ivospemin (SBP-101) has completed Phase Ia/Ib clinical trials for metastatic pancreatic ductal adenocarcinoma, while Flynpovi is in Phase III clinical trials. The company is in a critical stage of development with significantly diminished market valuation as of mid-2026.
Cyborg Score Rationale
As of May 29, 2026, Panbela's stock price stood at $0.01 with a market cap of $53.4K. The stock has declined 96.1% over the past year. The company is pre-revenue and heavily dependent on clinical trial progression.
Top Insights
Extreme liquidity crisis with market cap under $250K (as of June 2026) and near-penny-stock valuation
Two-pronged clinical strategy spanning Phase III (Flynpovi) and completed Phase Ib (Ivospemin) programs
Company raised approximately $8.5 million in June 2023 to fund clinical development
Clinical stage with no revenue; survival dependent on clinical success and capital access
Named Competitors
Aura Biosciences — Oncology-focused biopharmaceutical company
Sarepta Therapeutics — Gene therapy and RNA therapeutics
Amicus Therapeutics — Rare and genetic disease therapies
Recent Developments
(June 2023) Completed approximately $8.5 million public offering
(April 2024) Filed proxy statement for shareholder matters
(May 2026) Stock trading at $0.01 with market capitalization of $53.4K
Open the full interactive Panbela Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.